Physician Views snap-poll: Will Novartis' Mayzent disrupt the multiple sclerosis market?

Approved earlier this month by the FDA with a broad label for relapsing forms of multiple sclerosis, Novartis' oral drug Mayzent also became the first treatment specifically authorised for patients with active secondary progressive disease. Analysts were quick to highlight the opportunity cited by Novartis to target patients with relapsing remitting MS who are 'in transition' to secondary progressive disease.

Analysis - ViewPoints: Mayzent - everything you need to know about Novartis' new multiple sclerosis treatment

To get a better understanding of how Mayzent may impact the treatment landscape we are snap-polling US neurologists…

_________

Q. Mayzent (siponimod) has been approved by the FDA for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing remitting MS and active secondary progressive MS in adults (full label here).

Approval was based on data from the Phase III EXPAND trial, showing that Mayzent significantly reduced the risk of three-month confirmed disability progression in patients with active secondary progressive MS by 21 percent versus placebo. In the study, the drug also reduced the annualised relapse rate by 55 percent.

Mayzent will have a list price of $88,000 per year. Most patients will not require a first dose observation, unless they have certain pre-existing cardiac conditions.

How disruptive an effect do you think Mayzent will have on the MS treatment landscape?

Not disruptive

Slightly disruptive

Moderately disruptive

Very disruptive

Extremely disruptive

_________

Q. How compelling a treatment option do you think Mayzent is for relapsing remitting patients who are 'in transition' to secondary progressive MS?

Not compelling

Slightly compelling

Moderately compelling

Very compelling

Extremely compelling

_________

Q. How compelling a treatment option do you think Mayzent is for patients who have active secondary progressive MS?

Not compelling

Slightly compelling

Moderately compelling

Very compelling

Extremely compelling

_________

Q. What impact do you think the availability of Mayzent will have on increasing diagnosis rates for secondary progressive MS?

No impact

Slight impact

Moderate impact

Significant impact

Very significant impact

_________

Q. Which marketed MS therapies do you think Mayzent will most frequently be prescribed at the expense of?

Interferon betas

Copaxone

Aubagio

Gilenya

Tecfidera

Lemtrada

Ocrevus

Tysabri

_________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.